Suven Life Sciences, a clinical-stage biopharmaceutical company focused on the development of novel treatments for Central Nervous System (CNS) disorders, is set to present significant study results at the 76th American Academy of Neurology (AAN) Annual Meeting. The event will take place from April 13 to 18, 2024, in Denver, USA, as well as virtually. […]
Suven Life Sciences, a pioneering biopharmaceutical company specializing in Central Nervous System (CNS) disorders, recently announced the successful completion of its Phase-2 proof-of-concept study for samelisant. This novel medication was tested for its efficacy in reducing excessive daytime sleepiness (EDS) among adult patients with narcolepsy, both with and without cataplexy. The study reached its primary […]
Suven Life Sciences has announced the successful completion of enrollment for its phase-2 proof-of-concept (PoC) clinical study to evaluate the safety and efficacy of samelisant in adult narcolepsy patients, with and without cataplexy in the US and Canada. The Indian clinical-stage biopharmaceutical company, which specializes in central nervous system (CNS) disorder therapies, anticipates releasing the […]